Search Results

Adamis Pharmaceuticals Corporation announced the company changed its name to DMK Pharmaceuticals Corporation in order to better reflect its new strategic focus on advancing small molecules for the treatment of substance use disorders.

Adamis Pharmaceuticals Corporation, a commercial-stage biopharmaceutical company, announced the closing of its merger with DMK Pharmaceuticals Corporation.

Adamis Pharmaceuticals Corporation today announced the pricing of its public offering of 5,930,000 units at a public offering price of $1.35 per unit.

Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company, today announced financial results for the second quarter ended June 30, 2023, and provided an update on recent corporate developments.

Adamis Pharmaceuticals Corporation today announced the Company has committed to fund an unrestricted research grant to the Leiden University Medical Center (LUMC) Anesthesia and Pain Research Unit.

Adamis Pharmaceuticals Corporation today announced that Eboo Versi, MD, PhD, CEO of Adamis Pharmaceuticals is proud and excited to have participated in the White House Roundtable with Opioid Reversal Product Manufacturers, hosted by White House Office of National Drug Control Policy Director, Dr. Rahul Gupta.

Adamis Pharmaceuticals Corporation, a commercial-stage biopharmaceutical company, announced the closing of its public offering of 5,930,000 units, with each unit consisting of one share of common stock and one warrant to purchase one share of common stock.

Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) and DMK Pharmaceuticals, Corp. today announced that the companies have entered into an Agreement and Plan of Merger and Reorganization (the “Agreement”).

Adamis Pharmaceuticals Corporation announced financial results for the first quarter ended March 31, 2023, and provided an update on recent corporate developments.

Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company, today announced that its wholly owned subsidiary DMK Pharmaceuticals Corporation was the recipient of a grant from the National Institute on Alcohol Abuse And Alcoholism (NIAAA) of the National Institutes of Health (NIH) to support the development of a novel bifunctional small molecule for the treatment of Alcohol Use Disorder (AUD) (#R41AA030226).